Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial

  • Pasquale Rescigno
  • , Nuria Porta
  • , Laura Finneran
  • , Ruth Riisnaes
  • , Ines Figueiredo
  • , Suzanne Carreira
  • , Penny Flohr
  • , Susana Miranda
  • , Claudia Bertan
  • , Ana Ferreira
  • , Mateus Crespo
  • , Daniel Nava Rodrigues
  • , Bora Gurel
  • , Jenny Nobes
  • , Simon Crabb
  • , Zafar Malik
  • , Christy Ralph
  • , Ursula McGovern
  • , Peter Hoskin
  • , Robert J Jones
    • Alison Birtle, Joanna Gale, Peter Sankey, Suneil Jain, Duncan McLaren, Eliot Chadwick, Aude Espinasse, Emma Hall, Johann de Bono

Research output: Contribution to journal › Article › peer-review

12   Link opens in a new tab Citations (Scopus)
70 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science